Mark E. Haskins

9.4k total citations
254 papers, 7.2k citations indexed

About

Mark E. Haskins is a scholar working on Physiology, Genetics and Molecular Biology. According to data from OpenAlex, Mark E. Haskins has authored 254 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Physiology, 78 papers in Genetics and 74 papers in Molecular Biology. Recurrent topics in Mark E. Haskins's work include Lysosomal Storage Disorders Research (106 papers), Virus-based gene therapy research (54 papers) and Glycogen Storage Diseases and Myoclonus (28 papers). Mark E. Haskins is often cited by papers focused on Lysosomal Storage Disorders Research (106 papers), Virus-based gene therapy research (54 papers) and Glycogen Storage Diseases and Myoclonus (28 papers). Mark E. Haskins collaborates with scholars based in United States, France and Italy. Mark E. Haskins's co-authors include Donald F. Patterson, Peter F. Jezyk, Edward H. Schuchman, Katherine P. Ponder, Charles H. Vite, Calogera M. Simonaro, Mark S. Sands, John H. Wolfe, Geoffrey K. Aguirre and Robert J. Desnick and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Mark E. Haskins

250 papers receiving 6.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark E. Haskins United States 46 3.3k 2.5k 2.4k 1.3k 950 254 7.2k
John E. Wilkinson United States 51 2.4k 0.7× 6.4k 2.6× 1.8k 0.7× 1.3k 1.0× 827 0.9× 169 15.7k
Jane E. Barker United States 39 2.1k 0.6× 2.8k 1.1× 711 0.3× 382 0.3× 810 0.9× 119 7.1k
Stefan Karlsson Sweden 60 1.4k 0.4× 8.3k 3.3× 2.9k 1.2× 837 0.6× 1.1k 1.1× 196 13.9k
Elizabeth P. Henske United States 57 6.6k 2.0× 6.3k 2.5× 2.1k 0.9× 659 0.5× 1.1k 1.1× 187 12.4k
Alan Bernstein Canada 69 1.8k 0.6× 10.9k 4.4× 3.4k 1.4× 802 0.6× 2.3k 2.5× 219 19.4k
Jean‐Christophe Marine Belgium 66 866 0.3× 11.6k 4.6× 959 0.4× 677 0.5× 1.2k 1.2× 172 18.3k
Leslie G. Biesecker United States 65 978 0.3× 6.6k 2.6× 8.1k 3.3× 440 0.3× 616 0.6× 305 15.4k
Yoichi Shinkai Japan 66 910 0.3× 15.5k 6.2× 3.1k 1.3× 941 0.7× 487 0.5× 185 22.2k
Wen‐Hwa Lee United States 72 826 0.2× 13.9k 5.5× 4.8k 2.0× 821 0.6× 2.1k 2.2× 257 20.7k
Michael M. Shen United States 69 539 0.2× 10.4k 4.1× 2.5k 1.0× 445 0.3× 1.4k 1.5× 157 15.1k

Countries citing papers authored by Mark E. Haskins

Since Specialization
Citations

This map shows the geographic impact of Mark E. Haskins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Haskins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Haskins more than expected).

Fields of papers citing papers by Mark E. Haskins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Haskins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Haskins. The network helps show where Mark E. Haskins may publish in the future.

Co-authorship network of co-authors of Mark E. Haskins

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Haskins. A scholar is included among the top collaborators of Mark E. Haskins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Haskins. Mark E. Haskins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferla, Rita, Edoardo Nusco, John M. Cullen, et al.. (2020). Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors. Molecular Therapy — Methods & Clinical Development. 20. 247–257. 35 indexed citations
2.
Hinderer, Christian, Peter Bell, Nathan Katz, et al.. (2017). Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. Human Gene Therapy. 29(1). 15–24. 98 indexed citations
3.
Hinderer, Christian, Peter Bell, Jean‐Pierre Louboutin, et al.. (2016). Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. Molecular Genetics and Metabolism. 119(1-2). 124–130. 36 indexed citations
4.
Farris, Paul & Mark E. Haskins. (2016). Aligning Operations with Value-Created Insights: Facilitating the Financial Task. Management accounting quarterly. 17(3). 17. 1 indexed citations
5.
Bradbury, Allison M., et al.. (2015). A review of gene therapy in canine and feline models of lysosomal storage disorders. 776275620–776275620. 3 indexed citations
6.
Haskins, Mark E.. (2013). A Decade of DuPont Ratio Performance. Management accounting quarterly. 14(2). 24. 1 indexed citations
7.
Ferla, Rita, Thomas O’Malley, Roberto Calcedo, et al.. (2012). Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8. Human Gene Therapy. 24(2). 163–169. 38 indexed citations
8.
Smith, Lachlan J., Guilherme Baldo, Susan Wu, et al.. (2012). Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII. Molecular Genetics and Metabolism. 107(1-2). 153–160. 24 indexed citations
9.
Ellinwood, N. Matthew, Margret L. Casal, & Mark E. Haskins. (2006). 24 Gene Therapy for Metabolic Inherited Diseases in Dogs. Cold Spring Harbor Monograph Archive. 44. 473–495. 1 indexed citations
10.
Xu, Lingfei, Mark S. Sands, Bin Wang, et al.. (2004). In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice. Molecular Therapy. 10(1). 37–44. 18 indexed citations
11.
Kakkis, Emil, Edward H. Schuchman, Xingxuan He, et al.. (2001). Enzyme Replacement Therapy in Feline Mucopolysaccharidosis I. Molecular Genetics and Metabolism. 72(3). 199–208. 74 indexed citations
12.
Alroy, Joseph, Mark E. Haskins, & David E. Birk. (1999). Altered Corneal Stromal Matrix Organization is Associated with Mucopolysaccharidosis I, III and VI. Experimental Eye Research. 68(5). 523–530. 56 indexed citations
13.
Liedtka, Jeanne, et al.. (1998). El ciclo de generación o la vinculación entre el conocimiento y las relaciones. Harvard-Deusto business review. 54–65. 1 indexed citations
14.
Ray, Jharna, Mark E. Haskins, & Kunal Ray. (1998). Molecular diagnostic tests for ascertainment of genotype at the mucopolysaccharidosis type VII locus in dogs. American Journal of Veterinary Research. 59(9). 1092–1095. 9 indexed citations
15.
Haskins, Mark E., et al.. (1996). Corneal endothelium in mucopolysaccharide storage disorders. Morphologic studies in animal models.. PubMed. 15(1). 25–34. 27 indexed citations
16.
Wortman, Jeffrey A., et al.. (1994). Craniofacial abnormalities in animal models of mucopolysaccharidoses I, VI, and VII.. PubMed. 14(1). 7–15. 12 indexed citations
17.
Aguirre, Geoffrey K., Lawrence E. Stramm, & Mark E. Haskins. (1983). Feline mucopolysaccharidosis VI: General ocular and pigment epithelial pathology.. PubMed. 24(8). 991–1007. 29 indexed citations
18.
Jezyk, Peter F., Mark E. Haskins, & Carolyn Jones. (1979). Myocarditis of Probable Viral Origin in Pups of Weaning Age. Journal of the American Veterinary Medical Association. 174(11). 1204–1207. 12 indexed citations
19.
Haskins, Mark E., et al.. (1979). Mucopolysaccharidosis in a Domestic Short-Haired Cat—A Disease Distinct from That Seen in the Siamese Cat. Journal of the American Veterinary Medical Association. 175(4). 384–387. 15 indexed citations
20.
Jezyk, Peter F., et al.. (1976). Mucopolysaccharidosis in a Cat. Journal of the American Veterinary Medical Association. 169(3). 334–339. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John E. Wilkinson Breakdown of academic impact, for papers by Jane E. Barker Breakdown of academic impact, for papers by Stefan Karlsson Breakdown of academic impact, for papers by Elizabeth P. Henske Breakdown of academic impact, for papers by Alan Bernstein Breakdown of academic impact, for papers by Jean‐Christophe Marine Breakdown of academic impact, for papers by Leslie G. Biesecker Breakdown of academic impact, for papers by Yoichi Shinkai Breakdown of academic impact, for papers by Wen‐Hwa Lee Breakdown of academic impact, for papers by Michael M. Shen
Rankless by CCL
2026